Kiniksa Pharmaceuticals International plc Publishes Corporate Presentation on ARCALYST Growth and Cardiovascular Pipeline

Reuters02-24

Kiniksa Pharmaceuticals International plc Publishes Corporate Presentation on ARCALYST Growth and Cardiovascular Pipeline

Kiniksa Pharmaceuticals International plc highlighted ARCALYST (rilonacept) as its commercial product in recurrent pericarditis, noting $677.6 million in full-year 2025 net revenue and expected 2026 ARCALYST net product sales of $900 million to $920 million. The company reported approximately $1.5 billion in net revenue since ARCALYST’s launch and cited about 18% penetration into the U.S. multiple-recurrence population as of Q4 2025. The presentation also outlined clinical programs including KPL-387, an IL-1 receptor antagonist monoclonal antibody in a Phase 2/3 trial for recurrent pericarditis with Phase 2 data expected in the second half of 2026, and KPL-1161, with a Phase 1 first-in-human trial planned to initiate by the end of 2026. Kiniksa reported 2025 year-end cash reserves of approximately $414 million. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiniksa Pharmaceuticals International plc published the original content used to generate this news brief on February 24, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2613712903?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 21:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613712903","market":"fut","top_or_hot":-1,"title":"Kiniksa Pharmaceuticals International plc Publishes Corporate Presentation on ARCALYST Growth and Cardiovascular Pipeline","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kiniksa Pharmaceuticals International plc Publishes Corporate Presentation on ARCALYST Growth and Cardiovascular Pipeline\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kiniksa Pharmaceuticals International plc highlighted ARCALYST (rilonacept) as its commercial product in recurrent pericarditis, noting $677.6 million in full-year 2025 net revenue and expected 2026 ARCALYST net product sales of $900 million to $920 million. The company reported approximately $1.5 billion in net revenue since ARCALYST’s launch and cited about 18% penetration into the U.S. multiple-recurrence population as of Q4 2025. The presentation also outlined clinical programs including KPL-387, an IL-1 receptor antagonist monoclonal antibody in a Phase 2/3 trial for recurrent pericarditis with Phase 2 data expected in the second half of 2026, and KPL-1161, with a Phase 1 first-in-human trial planned to initiate by the end of 2026. Kiniksa reported 2025 year-end cash reserves of approximately $414 million. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiniksa Pharmaceuticals International plc published the original content used to generate this news brief on February 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kiniksa Pharmaceuticals International plc Publishes Corporate Presentation on ARCALYST Growth and Cardiovascular Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKiniksa Pharmaceuticals International plc Publishes Corporate Presentation on ARCALYST Growth and Cardiovascular Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-24 21:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kiniksa Pharmaceuticals International plc Publishes Corporate Presentation on ARCALYST Growth and Cardiovascular Pipeline\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kiniksa Pharmaceuticals International plc highlighted ARCALYST (rilonacept) as its commercial product in recurrent pericarditis, noting $677.6 million in full-year 2025 net revenue and expected 2026 ARCALYST net product sales of $900 million to $920 million. The company reported approximately $1.5 billion in net revenue since ARCALYST’s launch and cited about 18% penetration into the U.S. multiple-recurrence population as of Q4 2025. The presentation also outlined clinical programs including KPL-387, an IL-1 receptor antagonist monoclonal antibody in a Phase 2/3 trial for recurrent pericarditis with Phase 2 data expected in the second half of 2026, and KPL-1161, with a Phase 1 first-in-human trial planned to initiate by the end of 2026. Kiniksa reported 2025 year-end cash reserves of approximately $414 million. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiniksa Pharmaceuticals International plc published the original content used to generate this news brief on February 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL5K0rsS:1","article_id":"2613712903","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613712903","pubTimestamp":1771940911,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kiniksa Pharmaceuticals International plc highlighted ARCALYST  as its commercial product in recurrent pericarditis, noting $677.6 million in full-year 2025 net revenue and expected 2026 ARCALYST net product sales of $900 million to $920 million. The company reported approximately $1.5 billion in net revenue since ARCALYST’s launch and cited about 18% penetration into the U.S. multiple-recurrence population as of Q4 2025. The presentation also outlined clinical programs including KPL-387, an IL-1 receptor antagonist monoclonal antibody in a Phase 2/3 trial for recurrent pericarditis with Phase 2 data expected in the second half of 2026, and KPL-1161, with a Phase 1 first-in-human trial planned to initiate by the end of 2026. Kiniksa reported 2025 year-end cash reserves of approximately $414 million. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to p","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4505":"高瓴资本持仓","KNSA":"Kiniksa Pharmaceuticals Ltd."},"translate_title":"Kiniksa Pharmaceuticals International plc发布有关ARCALYST增长和心血管管道的公司演示文稿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KNSA":0.9},"content_text":"Kiniksa Pharmaceuticals International plc Publishes Corporate Presentation on ARCALYST Growth and Cardiovascular Pipeline\n    \n\n        Kiniksa Pharmaceuticals International plc highlighted ARCALYST (rilonacept) as its commercial product in recurrent pericarditis, noting $677.6 million in full-year 2025 net revenue and expected 2026 ARCALYST net product sales of $900 million to $920 million. The company reported approximately $1.5 billion in net revenue since ARCALYST’s launch and cited about 18% penetration into the U.S. multiple-recurrence population as of Q4 2025. The presentation also outlined clinical programs including KPL-387, an IL-1 receptor antagonist monoclonal antibody in a Phase 2/3 trial for recurrent pericarditis with Phase 2 data expected in the second half of 2026, and KPL-1161, with a Phase 1 first-in-human trial planned to initiate by the end of 2026. Kiniksa reported 2025 year-end cash reserves of approximately $414 million. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiniksa Pharmaceuticals International plc published the original content used to generate this news brief on February 24, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613712903","isCrawlerRequest":true}